Library Network
Alzheimer’s Disease
June 08
Current Awareness Bulletin
Most of the following articles are available online via the NHS Scotland eLibrary.
Please use the links where provided and your ATHENS password. A complete list of
available online journals and registration for ATHENS can be found at
http://www.elib.scot.nhs.uk/
If you would like to request print copies of any of the articles please contact your
nearest library or visit the library website for further details.
http://www.nhsggc.org.uk/libraryservices
Please note inter-library requests will only be done for South Glasgow NHS staff.
Please note, the articles you are accessing may be protected by copyright legislation, please
contact your librarian for a copyright declaration form if you are in any doubt. Or, consult the
Copyright Licensing Agency at http://www.cla.co.uk
If you have any questions regarding this or any other library services please contact
your librarian.
Compiled by C. Boulnois
Library Services Manager (South)
NHS Greater Glasgow & Clyde Library Network
Central Library
Southern General Hospital
1345 Govan Rd
G51 4TF
0141 201 2163
charlotte.boulnois@sgh.scot.nhs.uk
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
References
1.
[Anonymous]. Rivastigmine transdermal patch: A guide to its use in dementia of the
alzheimer's type. Drugs Ther Perspect. 2008; 24(4):5-8.
2.
Abramowitz L. Working with advanced dementia patients in a day care setting.
Journal of Gerontological Social Work. 2008; 50(3-4):25-35.
3.
Abrisqueta-Gomez J, Ostrosky-Solis F, Bertolucci PH, Bueno OF. Applicability of the
abbreviated neuropsychologic battery (NEUROPSI) in alzheimer disease patients.
Alzheimer Disease & Associated Disorders. 2008; 22(1):72-78.
4.
Aidaralieva NJ, Kamino K, Kimura R, et al. Dynamin 2 gene is a novel susceptibility
gene for late-onset alzheimer disease in non-APOE-epsilon4 carriers. J Hum Genet.
2008; 53(4):296-302.
5.
Alberici A, Bocchio L, Geroldi C, et al. Serum leptin levels are higher in females
affected by frontotemporal lobar degeneration than alzheimer's disease. Journal of
Neurology, Neurosurgery and Psychiatry. 2008; 79(6):712-715.
6.
Altmann LJP, McClung JS. Effects of semantic impairment on language use in
alzheimer's disease. Semin Speech Lang. 2008; 29(1):18-31.
7.
Amit T, Avramovich-Tirosh Y, Youdim MB, Mandel S. Targeting multiple alzheimer's
disease etiologies with multimodal neuroprotective and neurorestorative iron
chelators. FASEB Journal. 2008; 22(5):1296-1305.
8.
Anderson KN, Jamieson S, Graham AJ, Shneerson JM. REM sleep behaviour disorder
treated with melatonin in a patient with alzheimer's disease. Clin Neurol Neurosurg.
2008; 110(5):492-495.
9.
Andreasen N, Zetterberg H. Amyloid-related biomarkers for alzheimer's disease. Curr
Med Chem. 2008; 15(8):766-771.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
10.
Apostolova LG, Thompson PM. Mapping progressive brain structural changes in early
alzheimer's disease and mild cognitive impairment. Neuropsychologia. 2008;
46(6):1597-1612.
11.
Arimura H, Yoshiura T, Kumazawa S, et al. Automated method for identification of
patients with alzheimer's disease based on three-dimensional MR images. Acad
Radiol. 2008; 15(3):274-284.
12.
Armstrong RA, Syed AB, Smith CU. Density and cross-sectional areas of axons in
the olfactory tract in control subjects and alzheimer's disease: An image analysis
study. Neurological Sciences. 2008; 29(1):23-27.
13.
Arvanitakis Z, Schneider JA, Wilson RS, et al. Statins, incident alzheimer disease,
change in cognitive function and neuropathology. Neurology. 2008; 70(19 part
2):1795-1802.
14.
Bahia VS, Kok F, Marie SN, Shinjo SO, Caramelli P, Nitrini R. Polymorphisms of
APOE and LRP genes in brazilian individuals with alzheimer disease. Alzheimer
Disease & Associated Disorders. 2008; 22(1):61-65.
15.
Bakchine S, Loft H. Memantine treatment in patients with mild to moderate
alzheimer's disease: Results of a randomised, double-blind, placebo-controlled 6month study. J Alzheimer's Dis. 2008; 13(1):97-107.
16.
Ball SL, Holland AJ, Treppner P, Watson PC, Huppert FA. Executive dysfunction and
its association with personality and behaviour changes in the development of
alzheimer's disease in adults with down syndrome and mild to moderate learning
disabilities. British Journal of Clinical Psychology. 2008; 47(Pt 1):1-29.
17.
Banks S, Weintraub S. Self-awareness and self-monitoring of cognitive and
behavioral deficits in behavioral variant frontotemporal dementia, primary progressive
aphasia and probable alzheimer's disease. Brain Cogn. 2008; 67(1):58-68.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
18.
Banwait S, Galvan V, Zhang J, et al. C-terminal cleavage of the amyloid-beta
protein precursor at Asp664: A switch associated with alzheimer's disease. J
Alzheimer's Dis. 2008; 13(1):1-16.
19.
Barnham KJ, Bush AI. Metals in alzheimer's and parkinson's diseases. Curr Opin
Chem Biol. 2008; 12(2):222-228.
20.
Basurto-Islas G, Luna-Munoz J, Guillozet-Bongaarts AL, Binder LI, Mena R, GarciaSierra F. Accumulation of aspartic acid421- and glutamic acid
391-cleaved
tau in
neurofibrillary tangles correlates with progression in alzheimer disease. J Neuropathol
Exp Neurol. 2008; 67(5):470-483.
21.
Beher D. Gamma-secretase modulation and its promise for alzheimer's disease: A
rationale for drug discovery. Current Topics in Medicinal Chemistry. 2008; 8(1):3437.
22.
Bermejo P, Martin-Aragon S, Benedi J, et al. Peripheral levels of glutathione and
protein oxidation as markers in the development of alzheimer's disease from mild
cognitive impairment. Free Radic Res. 2008; 42(2):162-170.
23.
Beydoun MA, Beydoun HA, Wang Y. Obesity and central obesity as risk factors for
incident dementia and its subtypes: A systematic review and meta-analysis. Obesity
Reviews. 2008; 9(3):204-218.
24.
Bharadwaj P, Waddington L, Varghese J, Macreadie IG. A new method to measure
cellular toxicity of non-fibrillar and fibrillar alzheimer's abeta using yeast. J
Alzheimer's Dis. 2008; 13(2):147-150.
25.
Bier N, Van der Linden, M., Gagnon L, et al. Facee-name association learning in
early alzheimer's disease: A comparision of learning methods and their underlying
machanisms. Neuropsychological Rehabiltitation. 2008; 18(3):343-371.
26.
Blay SL, Piza Peluso Ede T. The public's ability to recognize alzheimer disease and
their beliefs about its causes. Alzheimer Disease & Associated Disorders. 2008;
22(1):79-85.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
27.
Bodil Roth E, Theander E, Londos E, et al. Pathogenesis of autoimmune diseases:
Antibodies against transglutaminase, peptidylarginine deiminase and protein-bound
citrulline in primary sjogren's syndrome, multiple sclerosis and alzheimer's disease.
Scand J Immunol. 2008; 67(6):626-631.
28.
Bossu P, Ciaramella A, Salani F, et al. Interleukin-18 produced by peripheral blood
cells is increased in alzheimer's disease and correlates with cognitive impairment.
Brain, Behavior, & Immunity. 2008; 22(4):487-492.
29.
Burns JM, Mayo MS, Anderson HS, Smith HJ, Donnelly JE. Cardiorespiratory fitness
in early-stage alzheimer disease. Alzheimer Disease & Associated Disorders. 2008;
22(1):39-46.
30.
Capurso C, Solfrizzi V, D'Introno A, et al. Short arm of chromosome 11 and sporadic
alzheimer's disease: Catalase and cathepsin D gene polymorphisms. Neurosci Lett.
2008; 432(3):237-242.
31.
Caputo M, Monastero R, Mariani E, et al. Neuropsychiatric symptoms in 921 elderly
subjects with dementia: A comparison between vascular and neurodegenerative
types. Acta Psychiatr Scand. 2008; 117(6):455-464.
32.
Carey CL, Woods SP, Damon J, et al. Discriminant validity and neuroanatomical
correlates of rule monitoring in frontotemporal dementia and alzheimer's disease.
Neuropsychologia. 2008; 46(4):1081-1087.
33.
Carlsson CM, Gleason CE, Hess TM, et al. Effects of simvastatin on cerebrospinal
fluid biomarkers and cognition in middle-aged adults at risk for alzheimer's disease. J
Alzheimer's Dis. 2008; 13(2):187-197.
34.
Carpentier N, Ducharme F, Kergoat M, Bergman H. Social representations of
barriers to care early in the careers of caregivers of persons with alzheimer's disease.
Res Aging. 2008; 30(3):334-357.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
35.
Castellani RJ, Lee H-, Zhu X, Nunomura A, Perry G, Smith MA. Alzheimer's disease:
Pathology vs etiology. International Journal of Neuroprotection and
Neuroregeneration. 2007; 4(1):36-40.
36.
Cechetto DF, Hachinski V, Whitehead SN. Vascular risk factors and alzheimer's
disease. Expert Review of Neurotherapeutics. 2008; 8(5):743-750.
37.
Cedazo-Minguez A. Apolipoprotein E and alzheimer's disease: Molecular mechanisms
and therapeutic opportunities.[see comment]. Journal of Cellular & Molecular
Medicine. 2007; 11(6):1227-1238.
38.
Chao S, Roberts JS, Marteau TM, Silliman R, Cupples LA, Green RC. Health behavior
changes after genetic risk assessment for alzheimer disease: The REVEAL study.
Alzheimer Disease & Associated Disorders. 2008; 22(1):94-97.
39.
Chapuis J, Hannequin D, Pasquier F, et al. Association study of the GAB2 gene with
the risk of developing alzheimer's disease. Neurobiol Dis. 2008; 30(1):103-106.
40.
Chetelat G, Fouquet M, Kalpouzos G, et al. Three-dimensional surface mapping of
hippocampal atrophy progression from MCI to AD and over normal aging as assessed
using voxel-based morphometry. Neuropsychologia. 2008; 46(6):1721-1731.
41.
Choe JY, Youn JC, Park JH, et al. The severe cognitive impairment rating scale--an
instrument for the assessment of cognition in moderate to severe dementia patients.
Dementia & Geriatric Cognitive Disorders. 2008; 25(4):321-328.
42.
Choi SH, Kim SY, Na HR, et al. Effect of ApoE genotype on response to donepezil in
patients with alzheimer's disease. Dementia & Geriatric Cognitive Disorders. 2008;
25(5):445-450.
43.
Ciccocioppo F, Lanuti P, Marchisio M, et al. Expression and phosphorylation of
protein kinase C isoforms in abeta(1-42) activated T lymphocytes from alzheimers
disease. International Journal of Immunopathology & Pharmacology. 2008; 21(1):2333.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
44.
Cilliler AE, Ozturk S, Ozbakir S. Serum magnesium level and clinical deterioration in
alzheimer's disease. Gerontology. 2007; 53(6):419-422.
45.
Cohen JT, Neumann PJ. Decision analytic models for alzheimer's disease: State of
the art and future directions. Alzheimer's and Dementia. 2008; 4(3):212-222.
46.
Connor KI, McNeese-Smith DK, Vickrey BG, et al. Determining care management
activities associated with mastery and relationship strain for dementia caregivers. J
Am Geriatr Soc. 2008; 56(5):891-897.
47.
Cosentino S, Scarmeas N, Helzner E, et al. APOE e4 allele predicts faster cognitive
decline in mild alzheimer disease. Neurology. 2008; 70(19 part 2):1842-1849.
48.
Crane MS. Classification and prediction of clinical alzheimer's diagnosis based on
plasma signalling proteins. Ann Clin Biochem. 2008; 45(2):231-232.
49.
Czigler B, Csikos D, Hidasi Z, et al. Quantitative EEG in early alzheimer's disease
patients - power spectrum and complexity features. International Journal of
Psychophysiology. 2008; 68(1):75-80.
50.
De Anna F, Attali E, Freynet L, et al. Intrusions in story recall: When over-learned
information interferes with episodic memory recall. evidence from alzheimer's
disease. Cortex. 2008; 44(3):305-311.
51.
de Jong D, Jansen R, Hoefnagels W, et al. No effect of one-year treatment with
indomethacin on alzheimer's disease progression: A randomized controlled trial. PLoS
ONE. 2008; 3(1):Arte Number: e1475. ate of Pubaton: 23 Jan 2008.
52.
de Vilhena Toledo Junqueira,LF. Cardiac sympathovagal modulation evaluated by
short-term heart interval variability is subtly impaired in alzheimer's disease. Geriatr
Gerontol Int. 2008; 8(2):109-118.
53.
Dickerson BC, Sperling RA. Functional abnormalities of the medial temporal lobe
memory system in mild cognitive impairment and alzheimer's disease: Insights from
functional MRI studies. Neuropsychologia. 2008; 46(6):1624-1635.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
54.
Ding B, Chen KM, Ling HW, et al. Diffusion tensor imaging correlates with proton
magnetic resonance spectroscopy in posterior cingulate region of patients with
alzheimer's disease. Dement Geriatr Cognit Disord. 2008; 25(3):218-225.
55.
Dominguez RO, Marschoff ER, Guareschi EM, et al. Insulin, glucose and glycated
hemoglobin in alzheimer's and vascular dementia with and without superimposed type
II diabetes mellitus condition. J Neural Transm. 2008; 115(1):77-84.
56.
Donahue JE, Johanson CE. Apolipoprotein E, amyloid-beta, and blood-brain barrier
permeability in alzheimer disease. Journal of Neuropathology & Experimental
Neurology. 2008; 67(4):261-270.
57.
El-Amouri SS, Zhu H, Yu J, Marr R, Verma IM, Kindy MS. Neprilysin: An enzyme
candidate to slow the progression of alzheimer's disease. Am J Pathol. 2008;
172(5):1342-1354.
58.
Erlangsen A, Zarit SH, Conwell Y. Hospital-diagnosed dementia and suicide: A
longitudinal study using prospective, nationwide register data. American Journal of
Geriatric Psychiatry. 2008; 16(3):220-228.
59.
Escudero J, Hornero R, Poza J, Abasolo D, Fernandez A. Assessment of classification
improvement in patients with alzheimer's disease based on magnetoencephalogram
blind source separation. Artif Intell Med. 2008; 43(1):75-85.
60.
Fan Y, Resnick SM, Wu X, Davatzikos C. Structural and functional biomarkers of
prodromal alzheimer's disease: A high-dimensional pattern classification study.
Neuroimage. 2008; 41(2):277-285.
61.
Farlow MR, Miller ML, Pejovic V. Treatment options in alzheimer's disease:
Maximizing benefit, managing expectations. Dementia & Geriatric Cognitive Disorders.
2008; 25(5):408-422.
62.
Fellgiebel A, Schermuly I, Gerhard A, et al. Functional relevant loss of long
association fibre tracts integrity in early alzheimer's disease. Neuropsychologia. 2008;
46(6):1698-1706.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
63.
FernandezDuque D, Black SE. Selective attention in early dementia of alzheimer
type. Brain Cognit. 2008; 66(3):221-231.
64.
Funke SA, Birkmann E, Henke F, et al. An ultrasensitive assay for diagnosis of
alzheimer's disease. Rejuvenation Research. 2008; 11(2):315-318.
65.
Gacia M, Safranow K, Gabryelewicz T, et al. Two polymorphisms of presenilin-2
gene (PSEN2) 5' regulatory region are not associated with alzheimer's disease (AD) in
the polish population. J Neural Transm. 2008; 115(1):85-90.
66.
Galvin JE, Cornblatt B, Newhouse P, et al. Effects of galantamine on measures of
attention: Results from 2 clinical trials in alzheimer disease patients with comparisons
to donepezil. Alzheimer Disease & Associated Disorders. 2008; 22(1):30-38.
67.
Garcia AM, Sisternas A, Hoyos SP. Occupational exposure to extremely low
frequency electric and magnetic fields and alzheimer disease: A meta-analysis. Int J
Epidemiol. 2008; 37(2):329-340.
68.
Gasparini M, Masciarelli G, Vanacore N, et al. A descriptive study on constructional
impairment in frontotemporal dementia and alzheimer's disease. European Journal of
Neurology. 2008; 15(6):589-597.
69.
Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients
with moderate to severe alzheimer's disease by memantine: A pooled data analysis.
Int J Geriatr Psychiatry. 2008; 23(5):537-545.
70.
Georges J, Jansen S, Jackson J, Meyrieux A, Sadowska A, Selmes M. Alzheimer's
disease in real life - the dementia carer's survey. Int J Geriatr Psychiatry. 2008;
23(5):546-551.
71.
Geula C, Nagykery N, Nicholas A, Wu CK. Cholinergic neuronal and axonal
abnormalities are present early in aging and in alzheimer disease. Journal of
Neuropathology & Experimental Neurology. 2008; 67(4):309-318.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
72.
Giffard B, Laisney M, Mezenge F, de la Sayette V, Eustache F, Desgranges B. The
neural substrates of semantic memory deficits in early alzheimer's disease: Clues
from semantic priming effects and FDG-PET. Neuropsychologia. 2008; 46(6):16571666.
73.
Giovagnoli AR, Erbetta A, Reati F, Bugiani O. Differential neuropsychological
patterns of frontal variant frontotemporal dementia and alzheimer's disease in a study
of diagnostic concordance. Neuropsychologia. 2008; 46(5):1495-1504.
74.
Giovannetti T, Bettcher BM, Brennan L, et al. Characterization of everyday
functioning in mild cognitive impairment: A direct assessment approach. Dementia &
Geriatric Cognitive Disorders. 2008; 25(4):359-365.
75.
Golan MP, Melquist S, Safranow K, et al. Analysis of UBQLN1 variants in a polish
alzheimer's disease patient: Control series. Dementia & Geriatric Cognitive Disorders.
2008; 25(4):366-371.
76.
Grimm MO, Grimm HS, Tomic I, Beyreuther K, Hartmann T, Bergmann C.
Independent inhibition of alzheimer disease beta- and gamma-secretase cleavage by
lowered cholesterol levels. J Biol Chem. 2008; 283(17):11302-11311.
77.
Guarch J, Marcos T, Salamero M, Gasto C, Blesa R. Mild cognitive impairment: A risk
indicator of later dementia, or a preclinical phase of the disease? Int J Geriatr
Psychiatry. 2008; 23(3):257-265.
78.
Haasl RJ, Ahmadi MR, Meethal SV, et al. A luteinizing hormone receptor intronic
variant is significantly associated with decreased risk of alzheimer's disease in males
carrying an apolipoprotein E epsilon4 allele. BMC Medical Genetics. 2008; 9:37.
79.
Harley TA, Jessiman LJ, MacAndrew SBG, Astell A. I don't know what I know:
Evidence of preserved semantic knowledge but impaired metalinguistic knowledge in
adults with probable alzheimer's disease. Aphasiology. 2008; 22(3):321-335.
80.
Harnish SM, Neils-Strunjas J. In search of meaning: Reading and writing in
alzheimer's disease. Semin Speech Lang. 2008; 29(1):44-59.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
81.
He Y, Chen Z, Evans A. Structural insights into aberrant topological patterns of
large-scale cortical networks in alzheimer's disease. Journal of Neuroscience. 2008;
28(18):4756-4766.
82.
Henry JD, Ruffman T, McDonald S, et al. Recognition of disgust is selectively
preserved in alzheimer's disease. Neuropsychologia. 2008; 46(5):1363-1370.
83.
Henry-Feugeas MC. Alzheimer's disease in late-life dementia: A minor toxic
consequence of devastating cerebrovascular dysfunction. Med Hypotheses. 2008;
70(4):866-875.
84.
Herholz K, Weisenbach S, Kalbe E. Deficits of the cholinergic system in early AD.
Neuropsychologia. 2008; 46(6):1642-1647.
85.
Hernandez M, Costa A, Juncadella M, Sebastian-Galles N, Rene R. Category-specific
semantic deficits in alzheimer's disease: A semantic priming study. Neuropsychologia.
2008; 46(4):935-946.
86.
Hoefer M, Allison SC, Schauer GF, et al. Fear conditioning in frontotemporal lobar
degeneration and alzheimer's disease. Brain. 2008; 131(6):1646-1657.
87.
Hommet C, Mondon K, Camus V, De Toffol B, Constans T. Epilepsy and dementia in
the elderly. Dementia & Geriatric Cognitive Disorders. 2008; 25(4):293-300.
88.
Hua X, Leow AD, Lee S, et al. 3D characterization of brain atrophy in alzheimer's
disease and mild cognitive impairment using tensor-based morphometry.
Neuroimage. 2008; 41(1):19-34.
89.
Ijuin M, Homma A, Mimura M, et al. Validation of the 7-minute screen for the
detection of early-stage alzheimer's disease. Dementia & Geriatric Cognitive
Disorders. 2008; 25(3):248-255.
90.
Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo
PiB-PET amyloid imaging in a typival case of alzheimer's disease. Brain. 2008;
131(6):1630-1645.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
91.
Inbar P, Bautista MR, Takayama SA, Yang J. Assay to screen for molecules that
associate with alzheimer's related beta-amyloid fibrils. Anal Chem. 2008; 80(9):35023506.
92.
Inestrosa NC, Dinamarca MC, Alvarez A. Amyloid-cholinesterase interactions.
implications for alzheimer's disease. FEBS Journal. 2008; 275(4):625-632.
93.
Itzhaki RF, Wozniak MA. Alzheimer's disease-like changes in herpes simplex virus
type 1 infected cells: The case for antiviral therapy. Rejuvenation Research. 2008;
11(2):319-320.
94.
Jarvik L, LaRue A, Blacker D, et al. Children of persons with alzheimer disease:
What does the future hold? Alzheimer Disease & Associated Disorders. 2008; 22(1):620.
95.
Jelles B, Scheltens P, van der Flier WM, Jonkman EJ, da Silva FH, Stam CJ. Global
dynamical analysis of the EEG in alzheimer's disease: Frequency-specific changes of
functional interactions. Clinical Neurophysiology. 2008; 119(4):837-841.
96.
Josephs KA, Whitwell JL, Knopman DS, et al. Abnormal TDP-43 immunoreactivity in
AD modifies clinicopathologic and radiologic phenotype. Neurology. 2008; 70(19 part
2):1850-1857.
97.
Kadir A, Andreasen N, Almkvist O, et al. Effect of phenserine treatment on brain
functional activity and amyloid in alzheimer's disease. Annals of Neurology. 2008;
63(5):621-631.
98.
Kanetaka H, Hanyu H, Hirao K, et al. Prediction of response to donepezil in
alzheimer's disease: Combined MRI analysis of the substantia innominata and SPECT
measurement of cerebral perfusion. Nucl Med Commun. 2008; 29(6):568-573.
99.
Kapaki E, Paraskevas GP, Papageorgiou SG, et al. Diagnostic value of CSF
biomarker profile in frontotemporal lobar degeneration. Alzheimer Disease &
Associated Disorders. 2008; 22(1):47-53.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
100.
Karas G, Sluimer J, Goekoop R, et al. Amnestic mild cognitive impairment:
Structural MR imaging findings predictive of conversion to alzheimer disease. Am J
Neuroradiol. 2008; 29(5):944-949.
101.
Karlawish J, Kim SY, Knopman D, van Dyck CH, James BD, Marson D. The views of
alzheimer disease patients and their study partners on proxy consent for clinical trial
enrollment. American Journal of Geriatric Psychiatry. 2008; 16(3):240-247.
102.
Karlawish JH, Zbrozek A, Kinosian B, Gregory A, Ferguson A, Glick HA. Preferencebased quality of life in patients with alzheimer's disease. Alzheimer's and Dementia.
2008; 4(3):193-202.
103.
Karlawish JH, Zbrozek A, Kinosian B, et al. Caregivers' assessments of preferencebased quality of life in alzheimer's disease. Alzheimer's and Dementia. 2008;
4(3):203-211.
104.
Khachaturian ZS, Petersen RC, Gauthier S, et al. A roadmap for the prevention of
dementia: The inaugural leon thal symposium. Alzheimer's and Dementia. 2008;
4(3):156-163.
105.
Klevay LM. Alzheimer's disease as copper deficiency. Med Hypotheses. 2008;
70(4):802-807.
106.
Koepsell TD, Kurland BF, Harel O, Johnson EA, Zhou X, Kukull WA. Education,
cognitive function and severity of neuropathology in alzheimer disease. Neurology.
2008; 70(19 part 2):1732-1739.
107.
Lamsa R, Helisalmi S, Herukka S-, et al. Genetic study evaluating LDLR
polymorphisms and alzheimer's disease. Neurobiol Aging. 2008; 29(6):848-855.
108.
Lange-Asschenfeldt C, Kojda G. Alzheimer's disease, cerebrovascular dysfunction
and the benefits of exercise: From vessels to neurons. Exp Gerontol. 2008;
43(6):499-504.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
109.
Lanni C, Racchi M, Mazzini G, et al. Conformationally altered p53: A novel
alzheimer's disease marker?. Mol Psychiatry. 2008; 13(6):641-647.
110.
Laske C, Leyhe T, Stransky E, et al. Association of platelet-derived soluble
glycoprotein VI in plasma with alzheimer's disease. J Psychiatr Res. 2008; 42(9):746751.
111.
Lavados M, Guillon M, Mujica MC, Rojo LE, Fuentes P, Maccioni RB. Mild cognitive
impairment and alzheimer patients display different levels of redox-active CSF iron. J
Alzheimer's Dis. 2008; 13(2):225-232.
112.
Levy E. Cystatin C: A potential target for alzheimer's treatment. Expert Review of
Neurotherapeutics. 2008; 8(5):687-689.
113.
Li J, Wu HM, Zhou RL, Liu GJ, Dong BR. Huperzine A for alzheimer's disease.
Cochrane Database of Systematic Reviews. 2008; (2):005592.
114.
Li J, Wu HM, Zhou RL, Liu GJ, Dong BR. Huperzine A for alzheimer's disease.
Cochrane Database Syst Rev. 2008; (2).
115.
Liang WS, Dunckley T, Beach TG, et al. Altered neuronal gene expression in brain
regions differentially affected by alzheimer's disease: A reference data set.
Physiological Genomics. 2008; 33(2):240-256.
116.
Liu Y, Wang K, Yu C, et al. Regional homogeneity, functional connectivity and
imaging markers of alzheimer's disease: A review of resting-state fMRI studies.
Neuropsychologia. 2008; 46(6):1648-1656.
117.
Livingston G, Coopoer C, Woods J, Milne A, Katona C. Successful ageing in
adversity: The LASER-AD longitudinal study. Journal of Neurology, Neurosurgery and
Psychiatry. 2008; 79(6):641-645.
118.
Locascio JJ, Fukumoto H, Yup L, et al. Plasma amyloid B-protein and C-reactive
protein in relation to the rate of progression of alzheimer disease. Archives of
Neurology. 2008; 65(6):776-785.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
119.
Lopez OL, Kuller LH, Mehta PD, et al. Plasma amyloid levels and the risk of AD in
normal subjects in the cariovascular health study. Neurology. 70; 19 part
1(1664):1671.
120.
Lyle S, Grizzell M, Willmott S, Benbow S, Clark M, Jolley D. Treatment of a whole
population sample of alzheimer's disease with donepezil over a 4-year period:
Lessons learned. Dementia & Geriatric Cognitive Disorders. 2008; 25(3):226-231.
121.
Macrae H. 'Making the best you can of it': Living with early-stage alzheimer's
disease. Sociol Health Illn. 2008; 30(3):396-412.
122.
Maczurek A, Shanmugam K, Munch G. Inflammation and the redox-sensitive AGERAGE pathway as a therapeutic target in alzheimer's disease. The Maillard Reaction
Recent Advances in Food and Biomedical Sciences.Annals of the New York Academy of
Sciences. 2008; 1126(pp 147-151):ate of Pubaton: Ar 2008.
123.
Mahon MM, Sorrell JM. Palliative care for people with alzheimer's disease. Nursing
Philosophy. 2008; 9(2):110-120.
124.
Mannion E. Alzheimer's disease: The psychological and physical effects of the
caregiver's role. part 2. Nurs Older People. 2008; 20(4):33-8, 39.
125.
Mannion E. Alzheimer's disease: The psychological and physical effects of the
caregiver's role. part 1. Nurs Older People. 2008; 20(4):27-32, 39.
126.
Mapstone M, Dickerson K, Duffy CJ. Distinct mechanisms of impairment in
cognitive ageing and alzheimer's disease. Brain. 2008; 131(6):1618-1629.
127.
Marks N, Berg MJ, Saito M, Saito M. Glucosylceramide synthase decrease in frontal
cortex of alzheimer brain correlates with abnormal increase in endogenous ceramides:
Consequences to morphology and viability on enzyme suppression in cultured primary
neurons. Brain Res. 2008; 1191:136-147.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
128.
Martin R, Griffith HR, Belue K, et al. Declining financial capacity in patients with
mild alzheimer disease: A one-year longitudinal study. American Journal of Geriatric
Psychiatry. 2008; 16(3):209-219.
129.
Mateo I, Sanchez-Juan P, Rodriguez-Rodriguez E, et al. 14-3-3 zeta and tau genes
interactively decrease alzheimer's disease risk. Dementia & Geriatric Cognitive
Disorders. 2008; 25(4):317-320.
130.
McCabe L. A holitic approach to caring for people with alzheimer's disease. Nursing
Standard. 2008; 22(42):50-56.
131.
McCurry SM, Pike KC, Vitiello MV, Logsdon RG, Teri L. Factors associated with
concordance and variability of sleep quality in persons with alzheimer's disease and
their caregivers. Sleep. 2008; 31(5):741-748.
132.
McDonald P. Making the connection between diet and nutrition and cardiovascular
and alzheimer's diseases. Explore: The Journal of Science & Healing. 2008; 4(2):148153.
133.
McGeown WJ, Shanks MF, Venneri A. Prolonged cholinergic enrichrnent influences
regional cortical activation in early alzheimer's disease. Neuropsychiatric Disease and
Treatment. 2008; 4(2):465-476.
134.
Moreira PI, Nunomura A, Nakamura M, et al. Nucleic acid oxidation in alzheimer
disease. Free Radic Biol Med. 2008; 44(8):1493-1505.
135.
Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET
diagnosis of mild cognitive impairment, alzheimer's disease, and other dementias.
Journal of Nuclear Medicine. 2008; 49(3):390-398.
136.
Muhammad A, Flores I, Zhang H, et al. Retromer deficiency observed in
alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and abeta
accumulation. Proc Natl Acad Sci U S A. 2008; 105(20):7327-7332.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
137.
Naurhashemi F, Ousset PJ, Gillette-Guyonnet S, Cantent C, Andrieu S, Vellas B. A
2-year follow-up of 233 very mild (CDR 0.5) alzheimer's disease patients (REAL.FR
cohort). Int J Geriatr Psychiatry. 2008; 23(5):460-465.
138.
Nazem A, Mansoori GA. Nanotechnology solutions for alzheimer's disease:
Advances in research tools, diagnostic methods and therapeutic agents. J Alzheimer's
Dis. 2008; 13(2):199-223.
139.
Neve RL. Alzheimer's disease sends the wrong signals--a perspective. Amyloid.
2008; 15(1):1-4.
140.
Nobili F, Koulibaly PM, Rodriguez G, et al. 99mTc-HMPAO and 99mTc-ECD brain
uptake correlates of verbal memory in alzheimer's disease. The Quarterly Journal of
Nuclear Medicine & Molecular Imaging. 2007; 51(4):357-363.
141.
Nordberg A. Amyloid imaging in alzheimer's disease. Neuropsychologia. 2008;
46(6):1636-1641.
142.
Okamura N, Funaki Y, Tashiro M, et al. In vivo visualization of donepezil binding in
the brain of patients with alzheimer's disease. Br J Clin Pharmacol. 2008; 65(4):472479.
143.
Okura Y, Matsumoto Y. DNA vaccine therapy for alzheimer's disease: Present
status and future direction. Rejuvenation Research. 2008; 11(2):301-308.
144.
Olson RE, Albright CF. Recent progress in the medicinal chemistry of gammasecretase inhibitors. Current Topics in Medicinal Chemistry. 2008; 8(1):17-33.
145.
Ousset PJ, Nourhashemi F, Reynish E, Vellas B. Nutritional status is associated with
disease progression in very mild alzheimer disease. Alzheimer Disease & Associated
Disorders. 2008; 22(1):66-71.
146.
Pankhurst Q, Hautot D, Khan N, Dobson J. Increased levels of magnetic iron
compounds in alzheimer's disease. J Alzheimer's Dis. 2008; 13(1):49-52.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
147.
Parente DB, Gasparetto EL, da Cruz LC,Jr, et al. Potential role of diffusion tensor
MRI in the differential diagnosis of mild cognitive impairment and alzheimer's disease.
AJR.American Journal of Roentgenology. 2008; 190(5):1369-1374.
148.
Patel NS, Quadros A, Brem S, et al. Potent anti-angiogenic motifs within the
alzheimer beta-amyloid peptide. Amyloid. 2008; 15(1):5-19.
149.
Patocka J, Jun D, Kuca K. Possible role of hydroxylated metabolites of tacrine in
drug toxicity and therapy of alzheimer's disease. Curr Drug Metab. 2008; 9(4):332335.
150.
Peraita H, Diaz C, Anllo-Vento L. Processing of semantic relations in normal aging
and alzheimer's disease. Archives of Clinical Neuropsychology. 2008; 23(1):33-46.
151.
Peretti CS, Ferreri F, Blanchard F, et al. Normal and pathological aging of attention
in presymptomatic huntington's, huntington's and alzheimer's disease, and
nondemented elderly subjects. Psychotherapy & Psychosomatics. 2008; 77(3):139146.
152.
Peretto I, La Porta E. Gamma-secretase modulation and its promise for alzheimer's
disease: A medicinal chemistry perspective. Current Topics in Medicinal Chemistry.
2008; 8(1):38-46.
153.
Persson J, Lind J, Larsson A, et al. Altered deactivation in individuals with genetic
risk for alzheimer's disease. Neuropsychologia. 2008; 46(6):1679-1687.
154.
Pettersen JA, Sathiyamoorthy G, Gao F, et al. Microbleed topography, leukoaraiosis
and cognition in probable alzheimer disease from the sunnybrook dementia study.
Archives of Neurology. 2008; 65(6):790-795.
155.
Pinals SL, Morgan AC. Distinguishing dementia with lewy bodies from parkinson's
disease dementia and alzheimer's disease: A geriatric case study. Clin Geriatr. 2008;
16(4):17-20.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
156.
Pomponi M, Bria P, Pomponi M. Is alzheimer's disease a synaptic disorder? J
Alzheimer's Dis. 2008; 13(1):39-47.
157.
Ponomareva NV, Korovaitseva GI, Rogaev EI. EEG alterations in non-demented
individuals related to apolipoprotein E genotype and to risk of alzheimer disease.
Neurobiol Aging. 2008; 29(6):819-827.
158.
Prasher VP, Kapadia HM, Haque. Season of birth: Dementia in alzheimer's disease
in adults with down syndrome. Int J Geriatr Psychiatry. 2008; 23(4):441-442.
159.
Rajendran L, Schneider A, Schlechtingen G, et al. Efficient inhibition of the
alzheimer's disease beta-secretase by membrane targeting. Science. 2008;
320(5875):520-523.
160.
Raymond SB, Skoch J, Hills ID, Nesterov EE, Swager TM, Bacskai BJ. Smart optical
probes for near-infrared fluorescence imaging of alzheimer's disease pathology.
European Journal of Nuclear Medicine & Molecular Imaging. 2008; 35(Suppl 1):S93-8.
161.
Rebollo A, Pou J, Alegret M. Cholesterol lowering and beyond: Role of statins in
alzheimer's disease. Aging Health. 2008; 4(2):171-180.
162.
Reed T, Perluigi M, Sultana R, et al. Redox proteomic identification of 4-hydroxy-2nonenal-modified brain proteins in amnestic mild cognitive impairment: Insight into
the role of lipid peroxidation in the progression and pathogenesis of alzheimer's
disease. Neurobiol Dis. 2008; 30(1):107-120.
163.
Reekum R. Donepezil was no better than placebo for agitation in patients with
alzheimer disease. ACP J Club. 2008; 148(2):33.
164.
Reiman EM, Chen K, Caselli RJ, et al. Cholesterol-related genetic risk scores are
associated with hypometabolism in alzheimer's-affected brain regions. Neuroimage.
2008; 40(3):1214-1221.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
165.
Reitz C, van Rooij FJA, de Maat MPM, et al. Matrix metalloproteinase 3 haplotypes
and dementia and alzheimer's disease. the rotterdam study. Neurobiol Aging. 2008;
29(6):874-881.
166.
Rimajova M, Lenzo NP, Wu JS, et al. Fluoro-2-deoxy-D-glucose (FDG)-PET in
APOEepsilon4 carriers in the australian population. J Alzheimer's Dis. 2008;
13(2):137-146.
167.
Ringman JM, Romano JD, Medina LD, et al. Increased prevalence of significant
recurrent headache in preclinical familial alzheimer's disease mutation carriers.
Dementia & Geriatric Cognitive Disorders. 2008; 25(4):380-384.
168.
Roked F, Patel A. Which aspects of cognitive function are best associated with
testamentary capacity in patients with alzheimer's disease?. Int J Geriatr Psychiatry.
2008; 23(5):552-553.
169.
Salminen A, Suuronen T, Kaarniranta K. ROCK, PAK, and toll of synapses in
alzheimer's disease. Biochemical & Biophysical Research Communications. 2008;
371(4):587-590.
170.
Salmon E, Lekeu F, Bastin C, Garraux G, Collette F. Functional imaging of cognition
in alzheimer's disease using positron emission tomography. Neuropsychologia. 2008;
46(6):1613-1623.
171.
Sampson E, Jenagaratnam L, McShane R. Metal protein attenuating compounds for
the treatment of alzheimer's disease. Cochrane Database Syst Rev. 2008; (1).
172.
Sando SB, Melquist S, Cannon A, et al. APOE epsilon4 lowers age at onset and is a
high risk factor for alzheimer's disease; A case control study from central norway. .
173.
Santa-Maria I, Cuadros R, Moreno FJ, Munoz V, Avila J, Hernandez F. Binding of
tau protein to the ends of ex vivo paired helical filaments. J Alzheimer's Dis. 2008;
13(2):177-185.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
174.
Scherder EJA, Eggermont L, Plooij B, et al. Relationship between chronic pain and
cognition in cognitively intact older persons and in patients with alzheimer's disease:
The need to control for mood. Gerontology. 2008; 54(1):50-58.
175.
Schnaider Beeri M, Silverman JM, Schmeidler J, et al. Clinical dementia rating
performed several years prior to death predicts regional alzheimer's neuropathology.
Dementia & Geriatric Cognitive Disorders. 2008; 25(5):392-398.
176.
Schnaider Beeri M, Silverman JM, Schmeidler J, et al. Clinical dementia rating
performed several years prior to death predicts regional alzheimer's neuropathology.
Dement Geriatr Cogn Disord. 2008; 25(5):392-398.
177.
Schott JM, Crutch SJ, Frost C, Warrington EK, Rossor MN, Fox NC.
Neuropsychological correlates of whole brain atrophy in alzheimer's disease.
Neuropsychologia. 2008; 46(6):1732-1737.
178.
Schultz MR, Lyons MJ, Franz CE, et al. Apolipoprotein E genotype and memory in
the sixth decade of life. Neurology. 2008; 70(19 part 2):1771-1777.
179.
Schupf N, Lee JH, Wei M, et al. Estrogen receptor-alpha variants increase risk of
alzheimer's disease in women with down syndrome. Dementia & Geriatric Cognitive
Disorders. 2008; 25(5):476-482.
180.
Seitz DP, Gruneir A, Rochon PA. Second-generation antipsychotics did not improve
outcomes and increased costs for patients with alzheimer disease and psychosis. ACP
J Club. 2008; 148(2):53.
181.
Seripa D, Matera MG, Franceschi M, et al. Association analysis of GRIN2B,
encoding N-methyl-D-aspartate receptor 2B subunit, and alzheimer's disease.
Dementia & Geriatric Cognitive Disorders. 2008; 25(3):287-292.
182.
Shaftel SS, Griffin WS, O'Banion MK. The role of interleukin-1 in
neuroinflammation and alzheimer disease: An evolving perspective. Journal of
Neuroinflammation. 2008; 5:7.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
183.
Shah RS, Lee H-, Xiongwei Z, Perry G, Smith MA, Castellani RJ. Current
approaches in the treatment of alzheimer's disease. Biomedicine and
Pharmacotherapy. 2008; 62(4):199-207.
184.
Sharer J. Tackling sundowning in a patient with alzheimer's disease. MEDSURG
Nursing. 2008; 17(1):27-29.
185.
Shea TB, Chan A. S-adenosyl methionine: A natural therapeutic agent effective
against multiple hallmarks and risk factors associated with alzheimer's disease. J
Alzheimer's Dis. 2008; 13(1):67-70.
186.
Shi C, Guo K, Yew DT, et al. Effects of ageing and alzheimer's disease on
mitochondrial function of human platelets. Exp Gerontol. 2008; 43(6):589-594.
187.
Shua-Haim J, Smith J, Picard F, et al. Steady-state pharmacokinetics of
rivastigmine in patients with mild to moderate alzheimer's disease not affected by coadministration of memantine: An open-label, crossover, single-centre study. Clinical
Drug Investigation. 2008; 28(6):361-374.
188.
Siedlecki KL, Honig LS, Stern Y. Exploring the structure of a neuropsychological
battery across healthy elders and those with questionable dementia and alzheimer's
disease. Neuropsychology. 2008; 22(3):400-411.
189.
Silva PN, Gigek CO, Leal MF, et al. Promoter methylation analysis of SIRT3,
SMARCA5, HTERT and CDH1 genes in aging and alzheimer's disease. J Alzheimer's
Dis. 2008; 13(2):173-176.
190.
Sluimer JD, Vrenken H, Blankenstein MA, et al. Whole-brain atrophy rate in
alzheimer disease. Neurology. 2008; 70(19 part 2):1836-1841.
191.
Small DH. Network dysfunction in alzheimer's disease: Does synaptic scaling drive
disease progression?. Trends Mol Med. 2008; 14(3):103-108.
192.
Solomon B. Immunological approaches for amyloid-beta clearance toward
treatment for alzheimer's disease. Rejuvenation Research. 2008; 11(2):349-357.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
193.
Solomon PR, Murphy CA. Early diagnosis and treatment of alzheimer's disease.
Expert Review of Neurotherapeutics. 2008; 8(5):769-780.
194.
Sparks MB. Inpatient care for persons with alzheimer's disease. Crit Care Nurs Q.
2008; 31(1):65-72.
195.
Spector A, Woods B, Orrell M. Cognitive stimulation for the treatment of
alzheimer's disease. Expert Review of Neurotherapeutics. 2008; 8(5):751-757.
196.
Squitti R, Ventriglia M, Barbati G, et al. 'Free' copper in serum of alzheimer's
disease patients correlates with markers of liver function. J Neural Transm. 2007;
114(12):1589-1594.
197.
Stallings TL. Association of alzheimer's disease and chlamydophila pneumoniae. J
Infect. 2008; 56(6):423-431.
198.
Steinitz M. Developing injectable immunoglobulins to treat cognitive impairment in
alzheimer's disease. Expert Opinion on Biological Therapy. 2008; 8(5):633-642.
199.
Sun X, Steffens DC, Au R, et al. Amyloid-associated depression: A prodromal
depression of alzheimer disease?. Arch Gen Psychiatry. 2008; 65(5):542-550.
200.
Taguchi H, Planque S, Nishiyama Y, et al. Catalytic antibodies to amyloid beta
peptide in defense against alzheimer disease. Autoimmunity Reviews. 2008;
7(5):391-397.
201.
Takeuchi M, Yamagishi S-. Possible involvement of advanced glycation endproducts (AGEs) in the pathogenesis of alzheimer's disease. Curr Pharm Des. 2008;
14(10):973-978.
202.
Tales A, Haworth J, Wilcock G, Newton P, Butler S. Visual mismatch negativity
highlights abnormal pre-attentive visual processing in mild cognitive impairment and
alzheimer's disease. Neuropsychologia. 2008; 46(5):1224-1232.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
203.
Tei E, Yamamoto H, Watanabe T, et al. Use of serum insulin-like growth factor-I
levels to predict psychiatric non-response to donepezil in patients with alzheimer's
disease. Growth Hormone & Igf Research. 2008; 18(1):47-54.
204.
Terriere E, Sharman M, Donaghey C, et al. alpha4beta2-nicotinic receptor binding
with 5-IA in alzheimer's disease: Methods of scan analysis. Neurochem Res. 2008;
33(4):643-651.
205.
Thomann PA, Toro P, Santos VD, Essig M, Schroder J. Clock drawing performance
and brain morphology in mild cognitive impairment and alzheimer's disease. Brain
Cogn. 2008; 67(1):88-93.
206.
Thornton-Wells TA, Moore JH, Martin ER, Pericak-Vance MA, Haines JL. Confronting
complexity in late-onset alzheimer disease: Application of two-stage analysis
approach addressing heterogeneity and epistasis. Genet Epidemiol. 2008; 32(3):187203.
207.
Toepper M, Beblo T, Thomas C, Driessen M. Early detection of alzheimer's disease:
A new working memory paradigm. Int J Geriatr Psychiatry. 2008; 23(3):272-278.
208.
Trivedi MA, Schmitz TW, Ries ML, et al. fMRI activation during episodic encoding
and metacognitive appraisal across the lifespan: Risk factors for alzheimer's disease.
Neuropsychologia. 2008; 46(6):1667-1678.
209.
Truchot L, Costes N, Zimmer L, et al. A distinct [18F]MPPF PET profile in amnestic
mild cognitive impairment compared to mild alzheimer's disease. Neuroimage. 2008;
40(3):1251-1256.
210.
Uhlhaas PJ, Pantel J, Lanfermann H, et al. Visual perceptual organization deficits in
alzheimer's dementia. Dementia & Geriatric Cognitive Disorders. 2008; 25(5):465475.
211.
Umegaki H, Itoh A, Suzuki Y, Nabeshima T. Discontinuation of donepezil for the
treatment of alzheimer's disease in geriatric practice. International Psychogeriatrics.
2008; 20(4):800-806.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
212.
Valla J, Schneider L, Niedzielko T, et al. Impaired platelet mitochondrial activity in
alzheimer's disease and mild cognitive impairment. Mitochondrion. 2006; 6(6):323330.
213.
van der Flier WM, Pijnenburg YA, Schoonenboom SN, Dik MG, Blankenstein MA,
Scheltens P. Distribution of APOE genotypes in a memory clinic cohort. Dementia &
Geriatric Cognitive Disorders. 2008; 25(5):433-438.
214.
van Marum RJ. Current and future therapy in alzheimer's disease. Fundam Clin
Pharmacol. 2008; 22(3):265-274.
215.
Vlad SC, Miller DR, kowall NW, Felson DT. Protective effects of NSAIDs on the
development of alzheimer disease. Neurology. 2008; 70(19 part 1):1672-1677.
216.
Wang B, Xie YC, Yang Z, et al. Lack of an association between alzheimer's disease
and the cystatin C (CST3) gene G73A polymorphism in mainland chinese. Dementia &
Geriatric Cognitive Disorders. 2008; 25(5):461-464.
217.
Wang DS, Uchikado H, Bennett DA, et al. Cognitive performance correlates with
cortical isopeptide immunoreactivity as well as alzheimer type pathology. J
Alzheimer's Dis. 2008; 13(1):53-66.
218.
Wang W, Shinto L, Connor WE, Quinn JF. Nutritional biomarkers in alzheimer's
disease: The association between carotenoids, n-3 fatty acids, and dementia severity.
J Alzheimer's Dis. 2008; 13(1):31-38.
219.
Wang X-, Ding H-. Alzheimer's disease: Epidemiology, genetics, and beyond.
Neuroscience Bulletin. 2008; 24(2):105-109.
220.
Warkentin S, Erikson C, Janciauskiene S. rCBF pathology in alzheimer's disease is
associated with slow processing speed. Neuropsychologia. 2008; 46(5):1193-1200.
221.
Werner P, Giveon SM. Discriminatory behavior of family physicians toward a
person with alzheimer's disease. International Psychogeriatrics. 2008; 20(4):824839.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
222.
Wilks SE, Vonk ME. Private prayer among alzheimer's caregivers: Mediating burden
and resiliency. Journal of Gerontological Social Work. 2008; 50(3-4):113-131.
223.
Wolfson W. Unraveling the tangled brain of alzheimer's. Chem Biol. 2008;
15(2):89-90.
224.
Wun KS, Miles LA, Crespi GA, et al. Crystallization and preliminary X-ray diffraction
analysis of the fab fragment of WO2, an antibody specific for the abeta peptides
associated with alzheimer's disease. Acta Crystallographica.Section F, Structural
Biology & Crystallization Communications. 2008; 64(Pt 5):438-441.
225.
Xiong C, Tang Y, van Belle G, Miller JP, Launer LJ, Morris JC. Evaluating the quality
of longitudinal statistical applications in original publications on alzheimer's disease.
Neuroepidemiology. 2008; 30(2):112-119.
226.
Xu Y, Xu G, Wu G, Antuono P, Rowe DB, Li SJ. The phase shift index for marking
functional asynchrony in alzheimer's disease patients using fMRI. Magn Reson
Imaging. 2008; 26(3):379-392.
227.
Yamada M, Mimori Y, Kasagi F, et al. Incidence of dementia, alzheimer disease,
and vascular dementia in a japanese population: Radiation effects research
foundation adult health study. Neuroepidemiology. 2008; 30(3):152-160.
228.
Yassa MA, Verduzco G, Cristinzio C, Bassett SS. Altered fMRI activation during
mental rotation in those at genetic risk for alzheimer disease. Neurology. 2008;
70(20):1898-1904.
229.
Yavuz BB, Yavuz B, Halil M, et al. Serum elevated gamma glutamyltransferase
levels may be a marker for oxidative stress in alzheimer's disease. International
Psychogeriatrics. 2008; 20(4):815-823.
230.
Yener G, Guntekin B, Basar E. Event-related delta oscillatory responses of
alzheimer patients. European Journal of Neurology. 2008; 15(6):540-547.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
231.
Zhang J, Sui J, Chi BC, Wei NC. Protein profile in neuroblastoma cells incubated
with S- and R-enantiomers of ibuprofen by iTRAQ-coupled 2-D LC-MS/MS analysis:
Possible action of induced proteins on alzheimer's disease. Proteomics. 2008;
8(8):1595-1607.
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.
If you would like to receive additional bulletin, please tick the bulletins you would like to receive,
ensure your name and address are on the front cover and return to the library address given
overleaf.
A&E
Allied Health Professionals
Alzheimer’s disease
Ambulatory care
Anaesthesia
Asthma
Burns/Dermatology/Plastics
Cancer: Pain
Cancer Supportive Care
Chaplain
Child Protection
Clinical Governance
Community Child Health
Community Nursing
Complaints
Coronary Intensive and High Dependency Care
Corporate Services
Day surgery
Dental Care Professionals
Dentistry
Digestive Diseases
Elderly Care Bulletin (Nursing)
Epilepsy
Guidelines
Gynaecologic Oncology
Head Injury
Health Promotion
Healthcare Associated Infection
Healthy Heart
IT
Lung Cancer
Medicine for the Elderly
Multiple Sclerosis
Neonatal Nursing and Midwifery
New Books
New Books (all sites & Nursing)
New Nurse
Nutrition
Orthopaedics
Paediatric Anaesthesia & Pain
Paediatric Oncology Nursing
Paediatric Physiotherapy
Paediatric Respiratory Medicine
Parkinson’s disease
Pharmacy
Prevention & Treatment of Alcohol &
Drug Abuse (Nursing)
Primary Care Mental Health
Rheumatology
Sarcoma
School nurses
Speech and Language Therapy
Spinal Injuries
Stroke (North Glasgow)
Stroke (South Glasgow)
Training, education and Management
(Nursing)
How to Access Electronic Articles
Many of the articles in this bulletin will be available online at the NHS Scotland eLibrary
1.
2.
3.
4.
5.
6.
Go to the NHS Scotland eLibrary http://www.elib.scot.nhs.uk
Click on Journals
Type in the journal title and click search.
Click on the appropriate title, then select the supplier you wish to use.
Put in your Athens password at the “Athens login” link.
Select the correct year, volume, issue and page number for the article you
want.
Please note, the articles you are accessing may be protected by copyright legislation, please
contact your librarian for a copyright declaration form if you are in any doubt. Or, consult the
Copyright Licensing Agency at http://www.cla.co.uk
If you have any questions regarding this or any other library services please contact
your librarian.
Compiled by C. Boulnois
Library Services Manager
NHS Greater Glasgow & Clyde Library Network
Central Library
Southern General Hospital
1345 Govan Rd
Glasgow
G51 4TF
0141 201 2163
charlotte.boulnois@sgh.scot.nhs.uk
Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
current articles and not intended to be exhaustive.